Literature DB >> 12739735

Relapses of hyperthyroidism in patients treated with radioiodine for nodular toxic goiter: relation to thyroid autoimmunity.

N Custro1, A Ganci, V Scafidi.   

Abstract

Relapses of hyperthyroidism after treatment with radioiodine for uni- or multi-nodular goiter may be accompanied by the appearance of TSAb. However, this phenomenon has only emerged from one retrospective study on Northern European patients, in which it was not possible to determine whether TSAb also appeared in treated patients who did not relapse. The present study aimed to assess the appearance, immunogenic nature and clinical characteristics of hyperthyroidism relapse after treatment with 131I for nodular toxic goiter in patients from the Mediterranean area. A retrospective study was performed on 76 consecutive patients, born and resident in Sicily and aged 56-80 yr at diagnosis, who were treated with radioiodine. Serum aliquots obtained from the patients before 131I treatment and during a follow-up of 36-144 months were assayed for TSAb and TPOAb. The clinical charts of the patients were also re-examined. Twenty-six out of 76 patients (36.8%) had a hyperthyroidism relapse after a first treatment with 131I. Eight of the 26 (30.7%) also relapsed after the second treatment. Three out of 26 (11.5%) relapsed after a third treatment. The 50 patients who required only one treatment and the 18 who relapsed only once were all TSAb-negative at baseline, while 3/8 (37.5%) who relapsed also after the second treatment were already TSAb-positive at baseline. TSAb became positive in 3/18 patients (16.7%) who relapsed once, and in 4/8 (50.0%) of those who relapsed after a second treatment. One of these 7 TSAb-positive relapsers was also already TPOAb-positive at baseline and another became TPOAb-positive after treatment. The presence of circulating TSAb in 3/76 (3.9%) patients before treatment for toxic goiter more probably points to a diagnosis of Marine-Lenhart's syndrome. In contrast, the de novo appearance of TSAb in the presence of hyperthyroidism relapse in 4/76 (5.3%) patients suggests the development of a Graves'-like disease after radioiodine treatment. This occurrence does not seem to have precise ethnic grounds, since the incidence we observed in Mediterranean patients was similar to that previously reported in Northern European patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12739735     DOI: 10.1007/BF03345136

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  17 in total

1.  Marine-Lenhart syndrome. Graves' disease with poorly functioning nodules.

Authors:  B Chandramouly; D Mann; R P Cunningham; E Giegerich
Journal:  Clin Nucl Med       Date:  1992-11       Impact factor: 7.794

2.  New simple method for thyroid volume determination by ultrasonography.

Authors:  A Szebeni; E Beleznay
Journal:  J Clin Ultrasound       Date:  1992-06       Impact factor: 0.910

Review 3.  Autoimmunity to the thyroid stimulating hormone receptor.

Authors:  S A Patibandla; B S Prabhakar
Journal:  Adv Neuroimmunol       Date:  1996

4.  Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules.

Authors:  B Nygaard; L Hegedüs; K G Nielsen; P Ulriksen; J M Hansen
Journal:  Clin Endocrinol (Oxf)       Date:  1999-02       Impact factor: 3.478

5.  Sequential presentation of a case of hyperthyroidism with autonomously functioning nodules and Graves' disease in the presence of IgG thyroid stimulators.

Authors:  P P Smyth; D Neylan; N M McMullan; D F Smith; T J McKenna
Journal:  Acta Endocrinol (Copenh)       Date:  1988-08

6.  Radioiodine therapy for multinodular toxic goiter.

Authors:  B Nygaard; L Hegedüs; P Ulriksen; K G Nielsen; J M Hansen
Journal:  Arch Intern Med       Date:  1999-06-28

7.  Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.

Authors:  B Nygaard; J Faber; A Veje; L Hegedüs; J M Hansen
Journal:  Thyroid       Date:  1999-05       Impact factor: 6.568

8.  Coexistence of an autonomously functioning thyroid nodule in a patient with Graves' disease: an unusual presentation of Marine-Lenhart syndrome.

Authors:  M Nishikawa; M Yoshimura; N Yoshikawa; N Toyoda; T Yonemoto; Y Ogawa; S Mori; S Tabata; T Tokoro; N Sakaguchi; M Inada
Journal:  Endocr J       Date:  1997-08       Impact factor: 2.349

9.  Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre.

Authors:  L Chiovato; F Santini; P Vitti; G Bendinelli; A Pinchera
Journal:  Clin Endocrinol (Oxf)       Date:  1994-06       Impact factor: 3.478

10.  Appearance of Graves'-like disease following regression of autonomously functioning thyroid nodules. Two case reports.

Authors:  P Orsolon; A Lupi; G De Antoni Migliorati; A Vianello Dri
Journal:  Minerva Endocrinol       Date:  1998-06       Impact factor: 2.184

View more
  3 in total

Review 1.  131I-Induced Graves' disease in patients treated for toxic multinodular goitre: systematic review and descriptive analysis.

Authors:  C Roque; C A Vasconcelos
Journal:  J Endocrinol Invest       Date:  2018-01-20       Impact factor: 4.256

Review 2.  The Marine-Lenhart syndrome revisited.

Authors:  Hans-Jürgen Biersack; Kim Biermann
Journal:  Wien Klin Wochenschr       Date:  2011-07-27       Impact factor: 2.275

3.  Graves disease following radioiodine therapy for toxic adenoma: Clinical case report.

Authors:  Guohua Shen; Futao Cui; Rui Huang; Anren Kuang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.